🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

MTNB MTNB

Company Profile ↓
$0.28
-71.35% 1Y
P/E-0.14
52W High$2.36
52W Low$0.24
EPS (TTM)$-2.00

Company Overview

MTNB (MTNB) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 55.7% CAGR over the past five years.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -65.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 55.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:55.71%
1 Year:-65.62%

Stock Price Performance

1 Year:-71.35%
6 Months:-53.39%
3 Months:-57.76%
1 Month:-55.72%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 2% of range
$0.24 $2.36
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)34.55 · Neutral
Price Performance
1M-55.72%
3M-57.76%
6M-53.39%
1Y-71.35%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 55.7% over 5 years.

CONS

  • Trading 88.3% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.14
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
55.71%
Profit 5Y
-
Revenue (YoY)
-65.62%
Earnings (YoY)
-

Profitability & Returns

ROCE
-121.15%
ROE
-
ROA
-
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.30
EPS (TTM)
$-2.00

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$5.87M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
18.03%
Chg in Prom Hold
-
FII / Inst Holding
2.59%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$1.10M
EBITDA
-
Free Cash Flow
$-15.50M
Operating Cash Flow
$-7.01M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue -------------------89.81K---95.83K33.33K---1.06M1.06M1.10M---------
Operating Income ----2.13M-2.42M-2.61M-2.57M-2.40M-2.16M-2.24M-1.62M-1.84M-4.49M-3.98M-3.41M-4.12M-3.40M-2.95M-4.10M-4.52M-4.56M-6.35M-5.77M-5.60M-6.35M-4.79M-6.88M-7.72M-5.92M-5.46M-5.59M-6.16M-6.13M-5.90M-5.84M-4.38M-1.95M-1.84M-1.58M-1.94M
Net Income -112.13K-343.31K-1.46M-2.14M-2.43M-2.61M-2.57M-2.40M-2.15M-2.24M-1.62M-1.84M-4.50M-3.97M-3.39M-4.11M-3.41M-2.94M-4.05M-3.34M-4.40M-5.05M-5.61M-5.45M-4.96M-4.79M-6.84M-5.98M-5.92M-5.46M-5.51M-6.06M-6.05M-5.82M-5.72M-4.28M-1.66M-5.25M-1.53M-1.92M
Diluted EPS -----------------------------0.03-0.03-0.03-0.03-1.39-1.34-1.15-0.85-0.33-1.03-0.40-0.30
R&D Expense 49.59K240.11K745.00K1.07M1.12M1.07M1.45M1.35M879.20K921.71K642.58K835.31K2.38M2.31M2.01M2.19M1.52M1.38M2.31M2.83M2.67M4.09M3.41M3.34M3.24M2.48M4.62M4.98M4.13M3.71M3.97M3.56M3.29M3.45M3.37M2.24M85.00K---

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -0194.49K0149.69K119.75K89.81K158.33K33.00K3.19M1.10M--
Operating Income -3.71M-10.46M-9.91M-8.26M-16.50M-14.65M-18.92M-24.21M-24.73M-24.59M-23.77M-24.59M-6.96M
Net Income -3.71M-10.22M-9.14M-7.60M-15.49M-14.08M-17.37M-22.45M-23.28M-21.00M-22.94M-24.25M-10.35M
Diluted EPS ----------0.10-5.28-4.98-2.00
R&D Expense 1.76M5.18M5.29M3.95M9.01M6.79M11.23M14.36M14.58M16.68M14.49M11.43M85.00K

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -11.33M3.36M8.41M9.82M14.42M19.94M40.24M70.97M61.33M44.82M25.10M12.64M7.21M
Total Equity -116.59K10.47M2.23M6.07M7.15M10.68M16.14M33.05M63.73M52.49M36.64M19.25M7.59M4.83M
Cash & Equivalents 424.36K10.84M2.59M3.23M4.11M7.31M12.45M22.17M12.43M21.03M6.83M4.79M7.28M4.00M
Total Liabilities -858.97K1.13M2.33M2.67M3.74M3.80M7.19M7.24M8.83M8.18M5.86M5.05M2.38M
Current Liabilities -858.97K1.12M1.13M1.44M1.77M2.84M3.10M3.57M4.35M4.29M2.62M2.67M1.46M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ---7.81M-6.12M-11.46M-10.32M-14.09M-17.37M-15.22M-19.16M-15.28M-15.88M-7.01M
Investing Cash Flow ---5.42K--942.18K-535.92K-6.01M-40.67M16.77M4.88M13.24M9.21M335.00K
Financing Cash Flow --8.46M7.00M15.60M15.87M29.85M48.05M6.96M79.00K-7.00K9.17M3.39M
Capital Expenditure -94.19K-288.52K-76.18K-0-942.18K-535.92K-405.60K-5.75K-260.00K-892.00K-218.00K--
Free Cash Flow ---7.89M-6.12M-12.40M-10.86M-14.50M-17.37M-15.48M-20.05M-15.50M--

Ratios (Annual)

Figures in %.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------
Operating Margin % ---5,096.0%--11,024.6%-12,230.9%-21,067.4%-15,288.4%-74,954.5%-771.3%-2,168.4%--
Net Margin % ---4,697.0%--10,345.9%-11,760.4%-19,343.4%-14,177.0%-70,554.5%-658.6%-2,093.2%--
ROE % -35.4%-458.8%-150.4%-106.3%-145.0%-87.2%-52.6%-35.2%-44.4%-57.3%-119.2%-319.5%-214.2%
ROCE % -35.4%-466.5%-136.2%-98.6%-130.4%-85.6%-50.9%-35.9%-43.4%-60.7%-105.7%-246.5%-121.1%

Shareholding Pattern

Insiders
18.03%
Institutions
2.59%
Public Float
3.16%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MTNB

Yahoo Finance hu, 30 Jul 2026

GH Power and TKMS Continue to Explore Clean Energy Collaboration in Support of Canada’s Future Patrol Submarine Project

TORONTO, July 30, 2026--GH Power and TKMS Explore Clean Energy Collaboration

Yahoo Finance Mon, 13 Jul 2026

GH Power, the Pioneering Clean Energy and Critical Materials Company, to Go Public through Business Combination with Matinas BioPharma

TORONTO, July 13, 2026--GH Power Inc. and Matinas BioPharma Holdings, Inc enter into Business Combination Agreement.

Yahoo Finance Mon, 13 Jul 2026

Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals

Will create publicly traded advanced clean energy company focused on modular carbon-free energy, green hydrogen, critical materials and industrial decarbonization Business Combination expected to provide public market platform to accelerate…

Yahoo Finance Fri, 26 Jun 2026

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

BEDMINSTER, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on June 24, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE Amer…

Yahoo Finance Fri, 03 Apr 2026

Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE Ame…

Yahoo Finance ue, 23 Sep 2025

Matinas BioPharma Holdings, Inc. (MTNB) Restructures Amid Challenges, Focuses on Oral Antifungal MAT2203

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Matinas BioPharma Holdings, Inc. is one of them. Matinas BioPharma Holdings, Inc. (NYSE:MTNB) is a clinical-stage biopharmaceutical compan…

MTNB — Frequently Asked Questions

What is the current share price of MTNB?

As of 2026-08-05 17:25 PDT, MTNB trades at $0.28 on NASDAQ/NYSE. Its 52-week range is $0.24 to $2.36.

What is the P/E ratio of MTNB?

MTNB trades at a trailing price-to-earnings (P/E) ratio of -0.14.

Is MTNB a good stock to buy?

This page provides a data-driven analysis of MTNB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space